Study shows ursodeoxycholic acid therapy holds promise

Published: 2011-01-17 06:57:00

Updated: 2011-01-17 06:57:00

High-dose ursodeoxycholic acid (UDCA) therapy, an active ingredient of Ursa, has shown promising results for its safety and tolerability in the treatment of nonalcoholic steatohepatitis (NASH), according to Daewoong Pharma.

In a 12-month study published by peer-view journal, Journal of Hepatology, a French research team said that serum liver biochemistries were stable or improved in 126 pat...

Fees

- Email service daily and homepage access.

$300 per month.
5 Email holders per each company.
Anual contract base.